Loading…
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $6.9B | $1.8B | $1.3B | $1.2B | 19.3% | 6.7% | 1.1% |
| 2024 | $6.5B | $1.9B | $1.3B | $1.4B | 21.9% | -4.7% | 4.0% |
| 2023 | $6.8B | $1.7B | $1.2B | $1.5B | 21.2% | -0.2% | -1.1% |
| 2022 | $6.8B | $1.9B | $1.3B | $1.0B | 23.6% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 6,848 | 6,833 | 6,510 | 6,948 |
| Operating Revenue | - | 6,848 | 6,833 | 6,510 | 6,948 |
| Cost Of Revenue | - | 3,126 | 3,368 | 2,975 | 3,305 |
| Gross Profit | - | 3,722 | 3,465 | 3,535 | 3,643 |
| Operating Expense | - | 2,104 | 2,115 | 2,047 | 2,164 |
| Research And Development | - | 467 | 481 | 479 | 455 |
| Selling General And Administration | - | 1,637 | 1,634 | 1,568 | 1,709 |
| Total Expenses | - | 5,230 | 5,483 | 5,022 | 5,469 |
| Operating Income | - | 1,618 | 1,350 | 1,488 | 1,479 |
| Total Operating Income As Reported | - | 1,618 | 1,350 | 1,488 | 1,479 |
| EBITDA | - | 1,905 | 1,705 | 1,874 | 1,835 |
| Normalized EBITDA | - | 1,905 | 1,705 | 1,874 | 1,835 |
| EBIT | - | 1,588 | 1,434 | 1,617 | 1,547 |
| Interest Income | - | 9 | 51 | 80 | 62 |
| Interest Expense | - | 84 | 95 | 96 | 112 |
| Net Interest Income | - | -75 | -44 | -16 | -50 |
| Other Non Operating Income Expenses | - | -39 | 33 | 49 | 6 |
| Other Income Expense | - | -39 | 33 | 49 | 6 |
| Interest Income Non Operating | - | 9 | 51 | 80 | 62 |
| Interest Expense Non Operating | - | 84 | 95 | 96 | 112 |
| Net Non Operating Interest Income Expense | - | -75 | -44 | -16 | -50 |
| Pretax Income | - | 1,504 | 1,339 | 1,521 | 1,435 |
| Tax Provision | - | 250 | 99 | 232 | 132 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 1,254 | 1,240 | 1,289 | 1,303 |
| Net Income From Continuing And Discontinued Operation | - | 1,254 | 1,240 | 1,289 | 1,303 |
| Net Income From Continuing Operation Net Minority Interest | - | 1,254 | 1,240 | 1,289 | 1,303 |
| Net Income | - | 1,254 | 1,240 | 1,289 | 1,303 |
| Net Income Common Stockholders | - | 1,254 | 1,240 | 1,289 | 1,303 |
| Net Income Including Noncontrolling Interests | - | 1,254 | 1,240 | 1,289 | 1,303 |
| Normalized Income | - | 1,254 | 1,240 | 1,289 | 1,303 |
| Diluted NI Availto Com Stockholders | - | 1,254 | 1,240 | 1,289 | 1,303 |
| Basic Average Shares | - | 299 | 294 | 290 | 284 |
| Diluted Average Shares | - | 300 | 296 | 291 | 285 |
| Reconciled Depreciation | - | 317 | 271 | 257 | 288 |
| Reconciled Cost Of Revenue | - | 3,126 | 3,368 | 2,975 | 3,305 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Agilent Technologies, Inc.this co. | A | $39.1B | 29.99 | 5.80 | 19.3% | 22.15 |
| IDEXX Laboratories, Inc. | IDXX | $44.5B | 42.05 | 27.75 | 66.0% | 30.06 |
| Humana Inc. | HUM | $42.0B | 35.35 | 2.38 | 6.7% | - |
| Becton, Dickinson and Company | BDX | $41.2B | 24.56 | 1.62 | 6.6% | 12.06 |
| Alnylam Pharmaceuticals, Inc. | ALNY | $40.5B |
| - |
| - |
| - |
| - |
| - |
| - |
| 129.21 |
| 51.37 |
| 39.8% |
| 61.62 |
| Waters Corporation | WAT | $37.0B | 57.52 | 14.43 | 25.1% | 36.74 |
| Zoetis Inc. | ZTS | $33.3B | 12.47 | 10.01 | 80.2% | 9.90 |
| IQVIA Holdings Inc. | IQV | $31.2B | 22.93 | 4.80 | 20.9% | 13.04 |
| Centene Corporation | CNC | $31.0B | -4.64 | 1.55 | -33.4% | -6.54 |
| Peer Median | - | 29.96 | 7.40 | 23.0% | 13.04 | |